WINT (Windtree Therapeutics) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Windtree Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-6.44 Mil. Windtree Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Windtree Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Windtree Therapeutics's current FCF Yield % is -1,533.00%.

The historical rank and industry rank for Windtree Therapeutics's FCF Margin % or its related term are showing as below:

During the past 13 years, the highest FCF Margin % of Windtree Therapeutics was 1631.15%. The lowest was -12552.53%. And the median was -1449.24%.

WINT's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -126.31
* Ranked among companies with meaningful FCF Margin % only.

Windtree Therapeutics FCF Margin % Historical Data

The historical data trend for Windtree Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windtree Therapeutics FCF Margin % Chart

Windtree Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-12,552.53

Windtree Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Windtree Therapeutics's FCF Margin %

For the Biotechnology subindustry, Windtree Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windtree Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Windtree Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Windtree Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-13.452	/	0
	=	%

Windtree Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-6.444	/	0
	=	%

Windtree Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Windtree Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622

Website

https://www.windtreetx.com

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Executives

Craig Fraser	director, officer: Chief Executive Officer	AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew	officer: VP, Controller, & CAO	WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck	director	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill	officer: SVP & CFO	4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc.	10 percent owner	7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc.	10 percent owner	7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman	officer: SVP & General Counsel	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis	officer: SVP & COO	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson	officer: SVP, Chief Development Officer	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh	director	75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott	director
Joseph M Mahady	director	16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber	director	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976